Veeral Sheth, MD: Identifying Durability, Safety of GB-102 in Wet AMD Treatment


Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.

In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the late breaking findings of the phase 2b ALTISSIMO trial data from the American Academy of Ophthalmology 2021 Meeting.

The data from the trial found the mean durability in 1 milligram GB-102 group was 12 months, in patients with wet age-related macular degeneration (wet AMD). Sheth noted the results of this data showed really good durability of the agent.

“We saw 55% of the patients in the one milligram group did not need rescue therapy in that last six months part of the observation, so they went 12 full months without needing any rescue therapy,” he said.

He continued with mentioning the 4 adverse events of iritis in the 1 milligram group, which were treated successfully with topical steroids. Sheth noted that anything that can be done to extend the life of a drug is valuable, balanced out with both efficacy and safety.

“Obviously, the nice thing about GB-102 Is it can be delivered via intravitreal injection,” he said. “So, it's easy to do in the clinic and monitor those patients as well.”

Sheth mentioned the recent FDA approval of port delivery systems, which can help to extend the life of a drug in a patient’s eye, leading to fewer injections and improved quality of life. He concluded with his excitement on the future of ophthalmology, noting it is an “exciting time to be in ophthalmology.”

“It's really exciting times that we have different mechanisms of actions that we're exploring different ways of extending dosing intervals,” Sheth said.

“Intravitreal Sunitinib Malate Depot (GB-102): Durability and Safety in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B),” was presented at AAO 2021.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.